{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:24:23Z","timestamp":1791606263928,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08012-5","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:55:53Z","timestamp":1775840153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CM512, a potentially novel IgG1-based bispecific antibody dual-targeting TSLP and IL-13, for the suppression of type 2 inflammation"],"prefix":"10.1186","volume":"24","author":[{"given":"Yunxiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxi","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"11","key":"8012_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.5588\/ijtld.14.0170","volume":"18","author":"I Asher","year":"2014","unstructured":"Asher I, Pearce N. Global burden of asthma among children. Int J Tuberc Lung Dis. 2014;18(11):1269\u201378.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"8012_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nm.2731","volume":"18","author":"ST Holgate","year":"2012","unstructured":"Holgate ST. Innate and adaptive immune responses in asthma. Nat Med. 2012;18(5):673\u201383.","journal-title":"Nat Med"},{"issue":"9","key":"8012_CR3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","volume":"22","author":"P Kolkhir","year":"2023","unstructured":"Kolkhir P, Akdis CA, Akdis M, Bachert C, Bieber T, Canonica GW, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discovery. 2023;22(9):743\u201367.","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"8012_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41423-025-01261-2","volume":"22","author":"I Ogulur","year":"2025","unstructured":"Ogulur I, Mitamura Y, Yazici D, Pat Y, Ardicli S, Li M, et al. Type 2 immunity in allergic diseases. Cell Mol Immunol. 2025;22(3):211\u201342.","journal-title":"Cell Mol Immunol"},{"key":"8012_CR5","doi-asserted-by":"crossref","unstructured":"Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-9.","DOI":"10.1056\/NEJMoa2034975"},{"issue":"1","key":"8012_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","volume":"13","author":"D Singh","year":"2025","unstructured":"Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, et al. Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial. Lancet Respiratory Med. 2025;13(1):47\u201358.","journal-title":"Lancet Respiratory Med"},{"key":"8012_CR7","doi-asserted-by":"publisher","first-page":"923362","DOI":"10.3389\/fimmu.2022.923362","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Jing D, Cheng J, Chen X, Shen M, Liu H. The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis. Front Immunol. 2022;13:923362.","journal-title":"Front Immunol"},{"issue":"24","key":"8012_CR8","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"26","key":"8012_CR9","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486\u201396.","journal-title":"N Engl J Med"},{"issue":"1","key":"8012_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","volume":"154","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Gim\u00e9nez-Arnau AM, Bernstein JA, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184\u201394.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"8012_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","volume":"389","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389(3):205\u201314.","journal-title":"N Engl J Med"},{"issue":"24","key":"8012_CR12","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","volume":"390","author":"SP Bhatt","year":"2024","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med. 2024;390(24):2274\u201383.","journal-title":"N Engl J Med"},{"issue":"1","key":"8012_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","volume":"23","author":"R Ebina-Shibuya","year":"2023","unstructured":"Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023;23(1):24\u201337.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"8012_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.alit.2022.12.001","volume":"72","author":"A Iwata","year":"2023","unstructured":"Iwata A, Toda Y, Furuya H, Nakajima H. Group 2 innate lymphoid cells in human asthma. Allergology Int. 2023;72(2):194\u2013200.","journal-title":"Allergology Int"},{"key":"8012_CR15","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fphar.2019.01387","volume":"10","author":"G Marone","year":"2019","unstructured":"Marone G, Granata F, Pucino V, Pecoraro A, Heffler E, Loffredo S, et al. The Intriguing Role of I nterleukin 13 in the Pathophysiology of Asthma. Front Pharmacol. 2019;10:1387.","journal-title":"Front Pharmacol"},{"key":"8012_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.immunol.21.120601.141142","volume":"21","author":"TA Wynn","year":"2003","unstructured":"Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21:425\u201356.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"8012_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/WOX.0b013e31821188e0","volume":"4","author":"EL Rael","year":"2011","unstructured":"Rael EL, Lockey RF. Interleukin-13 signaling and its role in asthma. World Allergy Organ J. 2011;4(3):54\u201364.","journal-title":"World Allergy Organ J"},{"key":"8012_CR18","doi-asserted-by":"publisher","unstructured":"Deiteren A, Krupka E, Imberdis K, Patel N, Staudinger H, Suratt B. Targeting of TSLP and IL-13 by the Novel NANOBODY\u00ae molecule SAR443765 reduces FeNO in asthma following single dose exposure. Am J Respir Crit Care Med. 2023;207:A6816. https:\/\/doi.org\/10.1164\/ajrccm-conference.2023.207.1_MeetingAbstracts.A6816","DOI":"10.1164\/ajrccm-conference.2023.207.1_MeetingAbstracts.A6816"},{"key":"8012_CR19","doi-asserted-by":"crossref","unstructured":"Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018 Sep 1;34(17):i884\u2013i890.","DOI":"10.1093\/bioinformatics\/bty560"},{"key":"8012_CR20","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim D, Paggi JM, Park C, et al. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37:907\u201315.","journal-title":"Nat Biotechnol"},{"key":"8012_CR21","doi-asserted-by":"crossref","unstructured":"Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, Whitwham A, Keane T, Shane A, McCarthy RM, Davies H, Li. Twelve years of SAMtools and BCFtools. GigaScience. 2021 Feb;10(2):giab008.","DOI":"10.1093\/gigascience\/giab008"},{"issue":"7","key":"8012_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923\u201330.","journal-title":"Bioinformatics"},{"issue":"2","key":"8012_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.intimp.2008.11.001","volume":"9","author":"LM Berry","year":"2009","unstructured":"Berry LM, Adams R, Airey M, et al. In vitro and in vivo characterisation of anti-murine IL-13 antibodies recognising distinct functional epitopes. Int Immunopharmacol. 2009;9(2):201\u20136. https:\/\/doi.org\/10.1016\/j.intimp.2008.11.001.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"8012_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.str.2010.01.003","volume":"18","author":"PJ Lupardus","year":"2010","unstructured":"Lupardus PJ, Birnbaum ME, Garcia KC. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2. Structure. 2010;18(3):332\u201342. https:\/\/doi.org\/10.1016\/j.str.2010.01.003.","journal-title":"Structure"},{"issue":"6","key":"8012_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1189\/jlb.1211622","volume":"91","author":"F Roan","year":"2012","unstructured":"Roan F, Bell BD, Stoklasek TA, Kitajima M, Han H, Ziegler SF. The multiple facets of thymic stromal lymphopoietin (TSLP) during allergic inflammation and beyond. J Leukoc Biol. 2012;91(6):877\u201386.","journal-title":"J Leukoc Biol"},{"key":"8012_CR26","doi-asserted-by":"publisher","first-page":"1356298","DOI":"10.3389\/fimmu.2024.1356298","volume":"15","author":"C Bachert","year":"2024","unstructured":"Bachert C, Hicks A, Gane S, Peters AT, Gevaert P, Nash S, et al. The interleukin-4\/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps. Front Immunol. 2024;15:1356298.","journal-title":"Front Immunol"},{"key":"8012_CR27","doi-asserted-by":"crossref","unstructured":"Brister DL, Omer H, Whetstone CE, Ranjbar M, Gauvreau GM. Multifactorial causes and consequences of tlsp production, function, and release in the asthmatic airway. Biomolecules. 2024;14(4).","DOI":"10.3390\/biom14040401"},{"issue":"1","key":"8012_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12016-025-09045-2","volume":"68","author":"L Sahnoon","year":"2025","unstructured":"Sahnoon L, Bajbouj K, Mahboub B, Hamoudi R, Hamid Q. Targeting IL-13 and IL-4 in Asthma: Therapeutic Implications on Airway Remodeling in Severe Asthma. Clin Rev Allergy Immunol. 2025;68(1):44.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"8012_CR29","doi-asserted-by":"publisher","first-page":"Jc128","DOI":"10.7326\/J23-0084","volume":"176","author":"RA Estrada","year":"2023","unstructured":"Estrada RA, Maselli DJ. In severe, uncontrolled asthma, tezepelumab reduced exacerbations over 1 y regardless of type 2 inflammation level. Ann Intern Med. 2023;176(11):Jc128.","journal-title":"Ann Intern Med"},{"issue":"8","key":"8012_CR30","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1016\/j.jaip.2019.05.030","volume":"7","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Cheng J, Li Y, He R, Pan P, Su X, et al. The Safety and Efficacy of Anti-IL-13 Treatment with Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2019;7(8):2661\u2013e713.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"8012_CR31","first-page":"e14456","volume":"17","author":"NMTJ Graham","year":"2024","unstructured":"Graham NMTJ, Morales C, Patel B, Hu J, Dias C, et al. First-in-human study of lunsekimig, a dual TSLP\/IL\u201313 targeting NANOBODY\u00ae molecule, in healthy subjects and patients with asthma. Clin Transl Sci. 2024;17(6):e14456.","journal-title":"Clin Transl Sci"},{"issue":"9","key":"8012_CR32","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s13555-022-00778-y","volume":"12","author":"J Cather","year":"2022","unstructured":"Cather J, Young M, DiRuggiero DC, Tofte S, Williams L, Gonzalez T. A Review of Phase 3 Trials of Dupilumab for the Treatment of Atopic Dermatitis in Adults, Adolescents, and Children Aged 6 and Up. Dermatol Ther (Heidelb). 2022;12(9):2013\u201338.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"8012_CR33","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1038\/s41467-024-46540-0","volume":"15","author":"C Bangert","year":"2024","unstructured":"Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine JP, Pilz M, et al. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun. 2024;15(1):2839.","journal-title":"Nat Commun"},{"issue":"1","key":"8012_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bjd.17791","volume":"181","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Simpson EL, Ardeleanu M, Tha\u00e7i D, Barbarot S, Bagel J, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator\u2019s Global Assessment: a pooled analysis of data from two phase III trials. Br J Dermatol. 2019;181(1):80\u20137.","journal-title":"Br J Dermatol"},{"key":"8012_CR35","doi-asserted-by":"crossref","unstructured":"Deiteren A, Krupka E, Bontinck L, Imberdis K, Conickx G, Bas S, et al. A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. Eur Respir J. 2025;65(4).","DOI":"10.1183\/13993003.01461-2024"},{"issue":"1","key":"8012_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bbrc.2018.08.064","volume":"504","author":"S Venkataramani","year":"2018","unstructured":"Venkataramani S, Low S, Weigle B, Dutcher D, Jerath K, Menzenski M, et al. Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP\/IL13 bispecific antibodies. Biochem Biophys Res Commun. 2018;504(1):19\u201324.","journal-title":"Biochem Biophys Res Commun"},{"issue":"337","key":"8012_CR37","doi-asserted-by":"publisher","first-page":"337ra65","DOI":"10.1126\/scitranslmed.aaf1938","volume":"8","author":"KM Vannella","year":"2016","unstructured":"Vannella KM, Ramalingam TR, Borthwick LA, Barron L, Hart KM, Thompson RW, et al. Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven inflammation and fibrosis. Sci Transl Med. 2016;8(337):337ra65.","journal-title":"Sci Transl Med"},{"issue":"11","key":"8012_CR38","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1002\/eji.200939302","volume":"39","author":"M Miyata","year":"2009","unstructured":"Miyata M, Nakamura Y, Shimokawa N, Ohnuma Y, Katoh R, Matsuoka S, et al. Thymic stromal lymphopoietin is a critical mediator of IL-13-driven allergic inflammation. Eur J Immunol. 2009;39(11):3078\u201383.","journal-title":"Eur J Immunol"},{"key":"8012_CR39","doi-asserted-by":"publisher","first-page":"A3189","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A3189","volume":"211","author":"Y Han","year":"2025","unstructured":"Han Y, Patki S, Xing H, Bodea C, Deantonio C, Hardin M, et al. Leveraging Transcriptomic Data to Investigate the Biology of IL13 and TSLP in COPD [abstract]. Am J Respir Crit Care Med. 2025;211:A3189.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"8012_CR40","doi-asserted-by":"publisher","first-page":"e13864","DOI":"10.1111\/cts.13864","volume":"17","author":"A Deiteren","year":"2024","unstructured":"Deiteren A, Bontinck L, Conickx G, et al. A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP\/anti-IL-13 NANOBODY\u00ae compound, in healthy volunteers. Clin Transl Sci. 2024;17(6):e13864. https:\/\/doi.org\/10.1111\/cts.13864.","journal-title":"Clin Transl Sci"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08012-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08012-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08012-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:46:10Z","timestamp":1776350770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08012-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8012"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08012-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human samples were approved by Shanghai Liquan Hospital ethics committee (20212002-C221). All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals and are complied with with the ARRIVE guidelines. All animal procedures were conducted in compliance with the relevant laws and regulations on the use and management of laboratory animals and the requirements of the Animal Ethics Committee of Breath Smooth Biotech Hangzhou CO., LTD. (Application No.: BSB-AUP-23142). Cynomolgus monkey studies were performed under number A2023058-K015-01, and mouse experiments under numbers BSB231424 and BSB23136.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y.Y. is an intern at Keymed Biosciences (Chengdu) Limited. Q.S., X.G., and B.C. are employees of Keymed Biosciences (Chengdu) Limited. The other authors declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"525"}}